德克萨斯州是美国肝细胞癌（HCC）年龄调整发病率最高的州1。德克萨斯癌症预防和研究机构（CPRIT）资助了德克萨斯肝细胞癌协作中心（TeCH），以协调、合作和宣传为总体目标，促进HCC 研究、教育和宣传活动，减少德克萨斯州的HCC死亡率2.方法：2022年9月17日，TeCH与贝克研究所卫生与生命科学中心共同主办了一次HCC多利益相关者会议。出席会议的有HCC研究人员、决策者、支付者、制药行业成员和德克萨斯州内外的患者宣传组织。本报告总结了会议的结果。此次会议的目标是确定不同的预防HCC的策略，并评估其实施的准备情况。我们呼吁开展以下计划：（1）全州性的病毒性肝炎消除计划；（2）增加NASH和肥胖意识的计划；（3）研究方案，开发将酒精相关性肝病治疗与酗酒障碍治疗相结合的医疗模式；以及（4）示范项目，评估识别和联系患有晚期纤维化和肝硬化的患者进入临床护理的有效性。版权所有©2023 AGA学会。由Elsevier Inc.出版。保留所有权利。

Texas has the highest age-adjusted incidence rate of hepatocellular carcinoma (HCC) in the United States.1 The Cancer Prevention and Research Institute of Texas (CPRIT) has funded the Texas Collaborative Center for Hepatocellular Cancer (TeCH) to facilitate HCC research, education and advocacy activities with the overall goal of reducing HCC mortality in Texas through coordination, collaboration and advocacy.2 METHODS: On September 17, 2022, TeCH co-sponsored a multi-stakeholder conference on HCC with the Baker Institute Center for Health and Biosciences. This conference was attended by HCC researchers, policy makers, payers, members from pharmaceutical industry and patient advocacy groups in and outside of Texas. This report summarizes the results of the conference.The goal of this meeting was to identify different strategies for preventing HCC and evaluate their readiness for implementation.We call for a statewide (1) viral hepatitis elimination program; (2) program to increase NASH and Obesity Awareness; (3) research program to develop health care models that integrate alcohol associated liver disease treatment and treatment for alcohol use disorder; and (4) demonstration projects to evaluate the effectiveness of identifying and linking patient with advanced fibrosis and cirrhosis to clinical care.Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.